Table 2. Baseline demographic and clinical characteristics of patients with newly-diagnosed, previously untreated multiple myeloma enrolled in phase I study of siltuximab in combination with RVD (N=11).
| Characteristic | No. | % |
|---|---|---|
| Age | ||
| ⩽65 years | 7 | 63.6 |
| >65 years | 4 | 36.4 |
| Sex | ||
| Male | 4 | 36.4 |
| Female | 7 | 63.6 |
| Race | ||
| Caucasian | 9 | 81.8 |
| African American | 2 | 18.2 |
| ISS stage | ||
| I | 7 | 63.6 |
| II | 2 | 18.2 |
| III | 2 | 18.2 |
| ECOG performance score | ||
| 0 | 6 | 54.5 |
| 1 | 5 | 45.5 |
| Cytogenetics karyotype | ||
| Normal/Diploid | 4 | 36.4 |
| Loss/del 13a | 2 | 18.2 |
| Hyperdiploidb | 2 | 18.2 |
| t(11;14) | 1 | 9.1 |
| Other | 1 | 18.2 |
| Unknown | 1 | 9.1 |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; ISS, International Staging System for multiple myeloma; RVD, lenalidomide, bortezomib, dexamethasone.
a
Includes one in combination with del 17p.
b
Alone or in combination with other cytogenetic abnormality.